HK Stock Movement | BAO PHARMA-B (02589) Rises Nearly 5% Against Market Trend, SJ02 Approved for Market Launch and KJ017 NDA Submitted

Stock News12-16

BAO PHARMA-B (02589) gained nearly 5% against the broader market trend, rising 3.79% to HKD 68.45 by the time of writing, with a trading volume of HKD 18.38 million.

Recently, BAO PHARMA-B officially listed on the main board of the Hong Kong Stock Exchange, closing up 138.82% on its debut. Its market capitalization has now exceeded HKD 20 billion.

According to its prospectus, BAO PHARMA-B strategically focuses on four key areas: large-volume subcutaneous drug delivery, antibody-mediated autoimmune diseases, assisted reproductive technology, and recombinant biopharmaceuticals. The company's pipeline includes 12 self-developed investigational products, comprising three core candidates (KJ017, KJ103, and SJ02 (Sheng Nuowa®)), four other clinical-stage candidates (BJ007, KJ015, SJ04, and KJ101), and five preclinical assets (BJ008, BJ009, BJ045, BJ047, and BJ044).

Analysts note that BAO PHARMA-B has established a unique "pyramid-shaped" pipeline structure, supported by its scenario-driven strategy, synthetic biology technological barriers, and cost-leading industrial advantages.

At the base of this pyramid are products with short clinical cycles, low costs, and high market demand certainty, such as the already-approved SJ02 and KJ017, for which a New Drug Application (NDA) has been submitted. These products address clear clinical pain points and enable rapid revenue generation, providing the company with self-sustaining cash flow and mitigating the financing concerns typical of pre-revenue biotech firms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment